(3S,10R,16S,E)-16-((S)-1-((2R,3R)-3-(4-(aminomethyl)phenyl)oxiran-2-yl)ethyl)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-6,6-dimethyl-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetraone | 1260431-28-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: (3S,10R,16S,E)-16-((S)-1-((2R,3R)-3-(4-(aminomethyl)phenyl)oxiran-2-yl)ethyl)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-6,6-dimethyl-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetraone
• 英文别名: (E)-(3S,10R,16S)-16-{(S)-1-[(2R,3R)-3-(4-Aminomethylphenyl)oxiranyl]ethyl}-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-6,6-dimethyl-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetraone；Cryptophycin analog 1；(3S,10R,13E,16S)-16-[(1S)-1-[(2R,3R)-3-[4-(aminomethyl)phenyl]oxiran-2-yl]ethyl]-10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone
• CAS: 1260431-28-4
• 化学式: C₃₇H₄₈ClN₃O₈
• 分子量: 698.256
• InChiKey: VGYCIPORVJQZDT-YXCXXXRFSA-N

物化性质

• 沸点：
  923.1±65.0 °C(Predicted)
• 密度：
  1.168±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  49
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.51
• 拓扑面积：
  159
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  (3S,10R,16S,E)-16-((S)-1-((2R,3R)-3-(4-(aminomethyl)phenyl)oxiran-2-yl)ethyl)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-6,6-dimethyl-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetraone 在 哌啶 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 (2S)-2-amino-N-((2S)-1-((4-((2R)-3-((S)-1-((3S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-6,6-dimethyl-2,5,9,12-tetraoxo-1,4-dioxa-8,11-diazacyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)amino)-1-oxopropan-2-yl)-3-methylbutanamide
  参考文献：
  名称：

  WO2018206635A5

  摘要：

  公开号：

  WO2018206635A5
• 作为产物：
  描述：

  5,5'-氧双(5-氧代戊酸) 以 甲醇 、 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 、 N,N-二甲基甲酰胺 为溶剂， 生成 (3S,10R,16S,E)-16-((S)-1-((2R,3R)-3-(4-(aminomethyl)phenyl)oxiran-2-yl)ethyl)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-6,6-dimethyl-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetraone
  参考文献：
  名称：

  NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF

  摘要：

  本发明提供了隐藻素偶联物及其包含它们的组合物。还提供了制备和使用此类化合物的方法。

  公开号：

  US20120225089A1

文献信息

• Di-substituted maleic amide linker for antibody drug conjugating and preparation method and use thereof
  申请人：Mabwell (shanghai) Bioscience Co., Ltd.

  公开号：US10987430B2

  公开（公告）日：2021-04-27

  Provided in the present invention are a di-substituted maleic amide linker conjugated to an antibody and a preparation method and use thereof. In particular, the present invention conjugates a strongly cytotoxic active substance to a biomacromolecule through a class of new linkers. The class of linkers can selectively act simultaneously with disulphide chains, so as to greatly improve the substance homogeneity of a conjugate. The conjugate prepared by the linker of the present invention has a high inhibitory activity on a cell strain expressing the corresponding antigen. Also provided is a method for preparing the above-mentioned conjugate and the use.

  本发明提供了一种二取代马来酰胺连接物与抗体结合的制备方法及其用途。具体而言，本发明通过一类新连接物将一种强烈细胞毒活性物质与生物大分子结合。这类连接物可以与二硫键同时选择性地作用，从而极大地提高结合物质的均一性。本发明连接物制备的结合物对表达相应抗原的细胞株具有高抑制活性。还提供了制备上述结合物的方法和用途。
• Cryptophycin antibody conjugates for the treatment of cancer
  申请人：SANOFI

  公开号：US11007275B2

  公开（公告）日：2021-05-18

  The present disclosure relates to compounds of formula (V): wherein Ab represents an antibody. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.

  本公开涉及式（V）化合物： 其中 Ab 代表抗体。本公开还涉及隐球菌苷有效载荷、隐球菌苷共轭物、含有它们的组合物及其治疗用途，特别是作为抗癌剂。本公开还涉及制备这些共轭物的工艺。
• NOUVEAUX CONJUGUES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
  申请人：SANOFI

  公开号：EP2448929A1

  公开（公告）日：2012-05-09
• ANTIBODY MOLECULES TO CD138 AND USES THEREOF
  申请人：VISTERRA, INC.

  公开号：US20190100588A1

  公开（公告）日：2019-04-04

  Antibody molecules that specifically bind to CD138 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.
• NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
  申请人：SANOFI

  公开号：US20200054760A1

  公开（公告）日：2020-02-20

  The present disclosure relates to compounds of formula (I): RCG1-L-P  (I) wherein RCG1 represents a reactive chemical group being reactive towards a chemical group present on a polypeptide such as an antibody; P represents H, OH or an activated O; and L represents a specific linker. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.